GS-5245 tablets 175 mg, GS-5245 tablets 350 mg
GS-US-611-6472
Phase 1 small_molecule active
Quick answer
GS-5245 tablets 175 mg, GS-5245 tablets 350 mg for Renal Impairment is a Phase 1 program (small_molecule) at Gilead Sciences International Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Gilead Sciences International Limited
- Indication
- Renal Impairment
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active